Why Is Esperion Therapeutics (ESPR) Up 6.4% Since Last Earnings Report?Zacks Investment Research • 06/03/21
Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet's Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21GlobeNewsWire • 05/15/21
Esperion Stock Plummets On Wider Than Expected Q1 Earnings Loss; Analysts Move To SidelinesBenzinga • 05/05/21
Esperion Therapeutics, Inc. (ESPR) CEO Timothy Mayleben on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
Esperion Therapeutics (ESPR) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/04/21
ESPERION Reports First Quarter 2021 Financial Results and Provides Company UpdateGlobeNewsWire • 05/04/21
Esperion Expands Partnership with Daiichi Sankyo Group to Additional TerritoriesGlobeNewsWire • 04/26/21
Why Is Esperion Therapeutics (ESPR) Down 5.6% Since Last Earnings Report?Zacks Investment Research • 03/25/21
NEXLETOL® (bempedoic acid) Tablet, ezetimibe and atorvastatin combination lowered bad cholesterol by 60.5% vs. placebo in Phase 2 studyGlobeNewsWire • 03/17/21
Esperion Therapeutics, Inc. (ESPR) CEO Timothy Mayleben on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/24/21
ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company UpdateGlobeNewsWire • 02/23/21